Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28733987 | 1.00 | CYP19A1 (0.80) | CYP19A1SIGMAR1HTR1ACYP26A1ACHE | |
| SCHEMBL30275056 | 1.00 | CYP19A1 (0.80) | CYP19A1SIGMAR1HTR1ACYP26A1ACHE | |
| SCHEMBL10033952 | 0.90 | SIGMAR1 (0.70) | CYP19A1SIGMAR1HTR1ACYP26A1ACHE | |
| SCHEMBL29679563 | 0.89 | CYP19A1 (0.70) | CYP19A1SIGMAR1HTR1ACYP26A1MAOB | |
| SCHEMBL13851845 | 0.89 | CYP19A1 (1.00) | CYP19A1SIGMAR1HTR1ACYP26A1 | |
| SCHEMBL31112261 | 0.89 | CYP19A1 (0.70) | CYP19A1SIGMAR1HTR1ACYP26A1MAOB | |
| SCHEMBL31112302 | 0.89 | CYP19A1 (0.70) | CYP19A1SIGMAR1HTR1ACYP26A1 | |
| SCHEMBL7247938 | 0.89 | CYP19A1 (0.70) | CYP19A1SIGMAR1HTR1ACYP26A1ACHE | |
| SCHEMBL28733981 | 0.89 | CYP19A1 (0.70) | CYP19A1SIGMAR1HTR1ACYP26A1MAOB | |
| SCHEMBL7249261 | 0.89 | CYP19A1 (0.70) | CYP19A1SIGMAR1HTR1ACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751118-B | Preparation method of chiral alpha-alkyl-alpha-benzyl tetralone compound | 苏州凯若利新材料科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-118221511-A | NNP-Mn catalyst, preparation method and method for synthesizing alpha-alkyl ketone | 西安近代化学研究所 | 2024-06-21 | — | — | CN | disclosed |
| CN-116751118-A | Preparation method of chiral alpha-alkyl-alpha-benzyl tetralone compound | 苏州凯若利新材料科技有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116102430-A | Alkylation synthesis method for in-situ catalytic alcohols | 中山大学 | 2023-05-12 | — | — | CN | disclosed |
| CN-111807971-B | Alkylation synthesis method for in-situ catalysis of alcohols | 中山大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-112694449-B | Asymmetric hydrogenation of ketone and alpha, beta-unsaturated ketone catalyzed by nonmetal catalyst | 中国科学院化学研究所 | 2022-05-24 | — | — | CN | disclosed |
| CN-112694449-A | Novel nonmetal catalyst for catalyzing asymmetric hydrogenation of ketone and alpha, beta-unsaturated ketone | 中国科学院化学研究所 | 2021-04-23 | — | — | CN | disclosed |
| CN-111807971-A | Alkylation synthesis method for in-situ catalysis of alcohols | 中山大学 | 2020-10-23 | — | — | CN | disclosed |
| CN-106478325-B | A method of synthesis alpha-alkyl ketone | 南京理工大学 | 2019-06-25 | — | — | CN | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
| US-6576632-B1 | Such as 3'-((Benzyl-(2-benzyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-carbamoyl)-methyl)-biphenyl-3-carboxylic acid | PFIZER INC | 2003-06-10 | — | — | US | disclosed |
| CN-1329589-A | N-aralkylamino 1,2,3, 4-tetrahydronaphthalenes as ligands of neuropeptide YY5 receptor | ORTHO MCNEIL PHARM INC (US) | 2002-01-02 | — | — | CN | disclosed |
| US-6117874-A | AROMATIC RING-SUBSTITUTED 4-HYDROXYTETRAHYDROQUINOLINES | PFIZER INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-5939452-A | TREATMENT OF ANTIINFLAMMATORY SKIN DISORDERS, AUTOIMMUNE DISORDERS | PFIZER INC (US) | 1999-08-17 | — | — | US | disclosed |
| CN-1166834-A | Benzopyram and benzo-fused compounds, their preparation and their use as leukotriene B4'(LTB4) antagonists | PFIZER (US) | 1997-12-03 | — | — | CN | disclosed |
| CN-1160399-A | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists | PFIZER (US) | 1997-09-24 | — | — | CN | disclosed |
| EP-0785935-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4' (LTB4) ANTAGONISTS | PFIZER INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011925-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4' (LTB4) ANTAGONISTS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| US-4738972-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | CYP19A1 2314/4885SIGMAR1 2522/4885HTR1A 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.